UK markets closed

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
23.27-0.78 (-3.24%)
As of 02:46PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close24.05
Open23.83
Bid23.31 x 800
Ask23.36 x 1200
Day's range23.24 - 24.30
52-week range13.47 - 33.09
Volume48,186
Avg. volume368,337
Market cap1.068B
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Merus Announces Financial Results for the Second Quarter and Provides Business Update

    - Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Zeno represents a potential new standard of care for NRG1+ cancer - Clinical update of MCLA-129 planned for second half of 2022; expansion cohorts including combination with osimertinib planned - Clinical update of petosemtamab (Peto) planned for first half of 2023 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (

  • Globe Newswire

    Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)

    34% overall response rate in 79 evaluable patients with measurable disease9.1 months median duration of responseTumor reduction in 70% of patientsZeno observed to be very well-toleratedPotential new standard of care for patients with NRG1+ cancerInvestor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology com

  • Globe Newswire

    Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10 at 12:45 p.m. ET. The webcast of the fireside chat will be contemporaneously available